Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNLVRS)

Drug Name

RWJ-68354 Drug Info

Synonyms

RWJ-68354; CHEMBL115769; 2-(4-FLUOROPHENYL)-4-METHOXY-3-(PYRIDIN-4-YL)-1H-PYRROLO[2,3-B]PYRIDIN-6-AMINE; rwj68354; SCHEMBL149547; BDBM15457; BDBM50215267; AKOS000280165

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 9819053
TTD Drug ID: DMNLVRS

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Approved Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Stress-activated protein kinase 2b (p38 beta)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[2]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[2]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[3]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[3]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[4]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[3]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[3]
Ro31-8220	DMDJLF0	Discovery agent	N.A.	Investigative	[3]
STAUROSPORINONE	DMU2H4K	Discovery agent	N.A.	Investigative	[3]
KT-5720	DM9J50F	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[5]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[5]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[6]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[2]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[5]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[7]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[7]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[7]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[7]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting MAP kinase p38 (MAPK12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SM-101	DMFX9O6	Idiopathic thrombocytopenic purpura	3B64.10	Approved (orphan drug)	[8]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[9]
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[10]
KC706	DMBX6C7	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[11]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[12]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[3]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[3]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[4]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[3]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MAP kinase p38 (MAPK12)	TTYT93M	MK12_HUMAN	Inhibitor	[1]
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[1]
Stress-activated protein kinase 2b (p38 beta)	TT73U6C	MK11_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.
2	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
3	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
4	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6	Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
7	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
8	Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
9	P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
10	Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
11	KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
12	Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
13	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.